This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Chemed (CHE) Q2 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Chemed (CHE) witnesses solid revenue growth across key subsidiaries in Q2 earnings.
Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in third-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
West Pharmaceutical's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in West Pharmaceutical Services.
Boston Scientific (BSX) Q2 Earnings Top, Margins Decline
by Zacks Equity Research
This time too Boston Scientific (BSX) refrains from providing any update on the full-year guidance.
Amedisys (AMED) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Amedisys' (AMED) second-quarter results reflect impressive performance by the Hospice division despite pandemic-led challenges.
Omnicell (OMCL) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
Omnicell's (OMCL) second-quarter revenues suffered due to slowdown in hospital purchasing decisions and product bookings owing to pandemic-led business disruptions.
West Pharmaceutical Services (WST) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 37.36% and 6.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why West Pharmaceutical (WST) Could Beat Earnings Estimates Again
by Zacks Equity Research
West Pharmaceutical (WST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
S&P 500 Turns Positive for 2020: 10 Top Stocks in ETF
by Sweta Killa
The S&P 500 index turns positive for 2020. We have highlighted 10 stocks that are leading the way in the ETF.
Here's Why You Should Retain DexCom (DXCM) Stock For Now
by Zacks Equity Research
DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.
Luminex (LMNX) Receives EUA for New COVID-19 Antibody Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its xMAP SARS-CoV-2 Multi-Antigen IgG Assay, which can be used to rapidly detect the presence of antibodies in people affected by the virus causing COVID-19.
Is West Pharmaceutical Services (WST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (WST) Outperforming Other Medical Stocks This Year?
Patterson Cos. (PDCO) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Patterson Cos. (PDCO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights include: Boise Cascade, Lakeland Industries, NextEra Energy, FormFactor and West Pharmaceutical Services
by Zacks Equity Research
Zacks.com featured highlights include: Boise Cascade, Lakeland Industries, NextEra Energy, FormFactor and West Pharmaceutical Services
Abiomed Gets FDA Nod for Data Streaming Via Impella Connect
by Zacks Equity Research
Abiomed's (ABMD) announcement of the FDA approval of one-way digital data streaming from the Impella Connect interface can boost patient outcomes further.
5 Low Leverage Stocks to Secure Your Portfolio in 2H2020
by Zacks Equity Research
To safeguard one's portfolio from notable losses, the real challenge for an investor is determining whether the organization's debt level is sustainable.
What's in Store for West Pharmaceutical's (WST) Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical Services (WST) is likely to have gained from continued strength in high-value product sales in Q2.
3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend
by Sriparna Ghosal
Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
Earnings Preview: West Pharmaceutical Services (WST) Q2 Earnings Expected to Decline
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ABC vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
ABC vs. WST: Which Stock Is the Better Value Option?
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Here's Why You Should Retain Integer Holdings Stock for Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from solid presence in the broader MedTech space and portfolio management.
Allscripts Extends Strategic Partnership With Microsoft
by Zacks Equity Research
Allscripts (MDRX) extends partnership with Microsoft that can help transform healthcare with smarter technology, thereby improving patient outcomes.
West Pharmaceutical (WST) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
4 Best MedTech Stocks to Combat Coronavirus Crisis on Strong ROE
by Debanjana Dey
Here are some MedTech stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.